News

Dr. Reddy’s Collaborates with Henlius for Groundbreaking Biosimilar

Dr. Reddy’s Collaborates with Henlius for Groundbreaking Biosimilar

Dr. Reddy’s Laboratories Partners with Henlius for Biosimilar HLX15

In an exciting new collaboration, Dr. Reddy’s Laboratories, a prominent global pharmaceutical company based in India, is joining forces with Henlius, a specialized biopharmaceutical firm. This partnership focuses on the commercialization of HLX15, an innovative biosimilar candidate designed to target multiple myeloma, a type of cancer that affects plasma cells in the bone marrow.

Highlights of the Collaboration

This collaboration combines Dr. Reddy’s well-established global commercial presence with Henlius’ expertise in developing high-quality biosimilars. The agreement outlines that Henlius will handle the development, manufacturing, and commercial supply of HLX15 while benefiting from a substantial potential compensation package that amounts up to $131.6 million. This figure includes an upfront payment of $33 million, along with additional milestone payments contingent on the product’s progression in the market. Furthermore, Henlius is set to receive royalties based on annual net sales, ensuring both companies have a vested interest in the success of HLX15.

The Significance of HLX15

HLX15 is an advanced, recombinant, fully human anti-CD38 monoclonal antibody injection that will be developed in both intravenous and subcutaneous forms. This biosimilar aims to provide a more accessible treatment option for patients afflicted with multiple myeloma, especially those who have faced barriers to accessing the original therapies, Darzalex® and Darzalex Faspro®.

Statements from Leadership

Erez Israeli, Chief Executive Officer of Dr. Reddy’s, expressed his optimism regarding the partnership, noting that it represents a significant step in the journey towards broader market penetration with biosimilars. Israeli highlighted the continual development of Dr. Reddy’s portfolio within emerging and now regulated markets, underlining the recent successes with pegfilgrastim and bevacizumab. He stated, “This latest collaboration with Henlius marks further progress in our regulated markets journey in biosimilars. We aim to ensure patients receive effective and affordable treatments.”

Dr. Jason Zhu, Executive Director and CEO of Henlius, echoed similar sentiments as he acknowledged the importance of their collaboration in addressing global health demands. He stated, “This partnership will enhance the global competitiveness of both organizations in oncology treatment, ultimately allowing us to reach and support more patients around the world.”

About HLX15

HLX15 has undergone rigorous development to ensure it meets the high standards set forth by global health authorities including the NMPA, EMA, and USFDA. Through extensive analytical similarity assessments and preclinical studies, HLX15 has demonstrated comparability with daratumumab, the current market leader. The successful completion of the Phase 1 clinical study indicates promising pharmacokinetic characteristics and safety profiles, indicating HLX15 is well-positioned for the next phases of clinical research.

Henlius: Focused on Innovative Solutions

Henlius has established itself as a formidable player in the biopharmaceutical space since its inception in 2010. With a commitment to offering affordable and innovative biologic medicines, the company has developed a robust pipeline of products that address pressing health needs, particularly in oncology and autoimmune diseases. With several products already approved both in China and internationally, Henlius is rapidly expanding its footprint in the pharmaceutical industry.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories, listed on multiple stock exchanges including NYSE (RDY), has been a leader in providing not just generics but also biosimilars and over-the-counter medications since its founding in 1984. The company operates with a steadfast commitment to affordable healthcare, focusing extensively on therapeutic areas such as oncology, cardiovascular, and gastrointestinal health. Their innovative pipeline continues to evolve, underscoring their mission of ‘Good Health Can’t Wait’ which puts patients first by ensuring access to necessary medications globally.

Frequently Asked Questions

What is HLX15?

HLX15 is a biosimilar candidate developed by Henlius, targeting the same indications as Darzalex® and Darzalex Faspro®, aimed at treating multiple myeloma.

What roles do Dr. Reddy’s and Henlius have in this partnership?

Dr. Reddy’s will focus on the commercialization of HLX15 in the U.S. and Europe while Henlius will manage development and manufacturing.

How much will Henlius potentially earn from this agreement?

Henlius may receive up to $131.6 million through upfront payments and various milestone payments, as well as royalties on sales.

What are the future plans for HLX15?

After successful Phase 1 studies, further comparative efficacy studies are being planned to progress HLX15 toward market approval.

What is the significance of this collaboration?

This collaboration is significant as it aims to enhance patient access to effective cancer treatments while leveraging both companies' strengths in the global market.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 231

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 417

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 211

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 193

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 207

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 249

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 432

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 286

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 196

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 367

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading

Top 5 Most Recently Viewed Articles

APT Miner Mobile App Revolutionizes Cloud Mining Experience

Updated Category News Views 352

APT Miner Mobile App: A New Era in Cryptocurrency Mining APT Miner has launched a groundbreaking mobile application that opens the door to easy cryptocurrency mining for everyone. With this new app, users can seamlessly engage in mining operations from their mobile devices, without the need for technical expertise or complicated setups. The platform caters to a wide range...

Continue Reading
Investors Urged to Act Before September Deadline in Alto Case

Updated Category News Views 233

Important Announcement for Alto Neuroscience Investors In a recent advisory, investors of Alto Neuroscience, Inc. (NYSE: ANRO) are being urged to secure legal counsel as the deadline for a pivotal class action lawsuit approaches. The deadline for lead plaintiffs to step forward is September 19, 2025, providing investors who are affected by a range of factors related to...

Continue Reading
Strategic Sale: McStarlite Co. Partners with Standex International

Updated Category News Views 244

Strategic Changes Ahead for McStarlite Co. In a significant move, Janes Capital Partners has announced its role as the exclusive advisor for McStarlite Co. in its acquisition by Standex International Corporation (NYSE:SXI). This partnership highlights Janes Capital Partners’ capability to navigate complex transactions in the aerospace sector. McStarlite Co.: A Leader in...

Continue Reading
Codis Accelerates Growth with 1315 Capital Investment

Updated Category News Views 185

Codis Secures Funding for Expansion Codis, a leading contract development and manufacturing organization (CDMO) specializing in spray drying and related technologies, is excited to announce a significant growth investment from 1315 Capital. This partnership aims to bolster Codis's manufacturing capabilities significantly, particularly at its Haverhill facility in the UK....

Continue Reading
A Decade of Growth: The Journey of an Investment in Guidewire

Updated Category News Views 174

The Growth Journey of Guidewire Software Guidewire Software (GWRE) has seen significant advancements in the last decade, marking an impressive annualized return of 17.03%. Over this period, it has outperformed the broader market by 4.38%, which speaks volumes about the company’s stability and growth potential. Understanding Guidewire’s Market Position With a current...

Continue Reading